The Asia Pacific transdermal drug delivery system market is expected to reach US$ 1,736.02 million by 2027 from US$ 1,199.69 million in 2019. The market is estimated to grow at a CAGR of 4.9% from 2020 to 2027.
The growth of the market is attributed to increasing prevalence of chronic diseases, growing demand for non-invasive drug delivery devices, and high demand for self-administration of drugs. However, the drug failure and recalls of transdermal drug delivery systems hinder the growth of the market in Asia Pacific.
The Asia Pacific transdermal drug delivery system market is expected to witness significant growth during the forecast period. The growth of the market is expected to be fastest in countries such as China, India, and Australia. The growth of the market in these countries is expected to be fastest due to growing technology, growing geriatric population, increasing prevalence of cardiovascular diseases, and growing demand for non-invasive medical devices. China is the largest market for transdermal drug delivery systems market. The growth of the transdermal drug delivery system market is primarily attributed to the growing technology in China and increasing developments by the market players. The excessive population in China, coupled with the rising prevalence of chronic diseases is offering immense growth opportunities in the transdermal patches and semisolid products for the pain management market. However, considering the geographic and economic operations between Asian countries and China, the countries are expected to witness challenge of COVID-19. The outbreak of disease has badly affected supply chain, and led to shortage of healthcare supplies in the region. Moreover, domestic start-ups backed by international funding have already started witnessing back out from investors putting the development of the products in jeopardy.
Asia Pacific Transdermal Drug Delivery System Market Revenue and Forecast to 2027 (US$ Million)
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
Asia Pacific Transdermal Drug Delivery System Market Segmentation
By Type
- Transdermal Patches
- Matrix Patches
- Microneedle Patches
- Drug-In-Adhesive Patches
- Reservoir Membrane Patches
- Transdermal Semisolids
- Sprays
- Gels
- Ointments
By Application
•
Cardiovascular Diseases• Central Nervous System Disorders
• Pain Management
• Hormonal Applications
- Transdermal Estrogen Therapy
- Testosterone Replacement Therapy
• Other Applications
By End User
•
Hospitals and Clinics• Home Care Settings
• Other End Users
By Country
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia Pacific
Company Profiles
- Novartis AG
- Luye Pharma Group
- Mylan N.V.
- GlaxoSmithKline plc
- Hisamitsu Pharmaceutical Co., Inc
Asia Pacific Transdermal Drug Delivery System Report Scope
Report Attribute | Details |
---|---|
Market size in 2019 | US$ 1,199.69 Million |
Market Size by 2027 | US$ 1,736.02 Million |
Global CAGR (2020 - 2027) | 4.9% |
Historical Data | 2017-2018 |
Forecast period | 2020-2027 |
Segments Covered |
By Type
|
Regions and Countries Covered | Asia-Pacific
|
Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset


- Hydrolyzed Collagen Market
- Explosion-Proof Equipment Market
- Bio-Based Ethylene Market
- Advanced Planning and Scheduling Software Market
- Customer Care BPO Market
- Smart Mining Market
- Sports Technology Market
- Emergency Department Information System (EDIS) Market
- Truck Refrigeration Market
- Small Molecule Drug Discovery Market

Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Type, Application, End User

Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Australia, China, Japan, South Korea
Trends and growth analysis reports related to Life Sciences : READ MORE..
- Novartis AG
- Luye Pharma Group
- Mylan N.V.
- GlaxoSmithKline plc
- Hisamitsu Pharmaceutical Co., Inc